Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401707 · ClinicalTrials.gov registry record · Phase 2
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
A Phase 2 study of Seizures and Status Epilepticus, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT06401707 is a Phase 2 study of Seizures and Status Epilepticus that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 52 participants, below the 933-participant average among 39 other Seizures trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06401707, a Phase 2 study of Seizures and Status Epilepticus, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Perampanel
Study Locations (1)
California
- Zuckerberg San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2026-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06401707
The ClinicalTrials.gov registry entry for NCT06401707 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 933-participant average among 39 other Seizures trials with a reported enrollment target (94% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Seizures appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06401707 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06401707 about?
NCT06401707 is a clinical study titled "PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest". Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of per...
What is the current status of trial NCT06401707?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2024-05-20. Estimated completion is 2026-10-20.
What conditions does trial NCT06401707 study?
This clinical trial studies the following conditions: Seizures, Status Epilepticus, Heart Arrest.
What interventions are being tested in trial NCT06401707?
The interventions under investigation include: Placebo (DRUG), Perampanel (DRUG).
Who is sponsoring clinical trial NCT06401707?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401707 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
RECRUITING · Phase 2
-
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Hypovitaminosis D in Neurocritical Patients
COMPLETED · Phase 2
-
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
COMPLETED · Phase 2
-
Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.